Judge Richard G. Andrews construed the one disputed claim term of plaintiffs’ U.S. Patent No. 7,815,934 covering plaintiffs’ EMBEDA® extended release capsules for oral use. in a one page order, Judge Andrews adopted plaintiffs’ proposed construction, construing the term “sequestering subunit” to mean “Any means for containing an aversive agent and preventing or substantially preventing the release thereof in the gastrointestinal tract when intact, i.e., when not tampered with.”
Pfizer Inc. v. Watson Laboratories, Inc. – Florida, C.A. No. 11-914-RGA (D. Del. Oct. 15, 2012)
Delaware IP Law Blog 